In breast cancer [8], clear cell renal cell carcinoma [15], colorectal cancer [16], and osteosarcoma [17], high HHLA2 expression is associated with invasive tumour behaviour and worse clinical outcomes. Here, HHLA2 is linked to colorectal cancer.